CNNSangamo Jumps to 13-Year High on HIV-Controlling Studies (1)BusinessweekSangamo BioSciences Inc. (SGMO:US), a drug developer focused on gene editing, rose to its highest value in 13 years on studies showing its treatment may help patients control HIV without daily therapy, potentially curing them. Sangamo jumped 23 percent …Chemotherapy helps HIV patients respond to Sangamo gene treatmentReutersSangamo Presents Clinical Data At CROI 2014 Demonstrating Enhancement Of …Wall Street JournalHIV cure hoped for in 2nd US babyCBC.caMedical News Today -New York Times -Livemintall 504 news articles …read more
Via: Google UK
Sangamo Jumps to 13-Year High on HIV-Controlling Studies (1) - Businessweek
Real Estate of Cebu
